Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|April 2, 2019
- Pharmaceutical Technology-04-02-2019
- Volume 43
- Issue 4
Multichannel Pipettes for 384-Well Plates
Eppendorf’s 16- and 24-channel pipettes can handle entire columns and rows of a 384-well plate in one step.
Eppendorf’s 16- and 24-channel pipettes can handle entire columns and rows of a 384-well plate in one step. An entire plate can be managed manually within a minute, and up to 24 reactions may be started and stopped simultaneously, according to the company.
The pipettes come with epT.I.P.S. 384 and ep Dualfilter T.I.P.S. 384 systems for improved security and comfort. The SOFTattach technology uses elastic forming grooves that contribute to a precise tip fit and seal. The company states that tip attachment forces are reduced by up to an additional 40% per tip. The system’s fine tip shape and coaxiality makes maneuvering samples into the tiny wells of a 384-well plate secure. The pipettes are available as both mechanical and electronic.
Articles in this issue
over 7 years ago
Cleaning Chromatography Resin Residues from Surfacesover 7 years ago
OSD Continuous Manufacturing Strategiesover 7 years ago
Channeling Customer Complaints into Qualityover 7 years ago
Continuous Manufacturing Gains Major Push from FDAover 7 years ago
Particles on Best Behaviorover 7 years ago
Spray Drying: Supporting Patient-Centric Drug Developmentover 7 years ago
Advanced Cell Penetrating Peptide Systems for Gene Therapyover 7 years ago
Degradation Pathways: A Case Study with Pegylated L-Asparaginaseover 7 years ago
Locking Fraudulent Materials Out of the Supply ChainRelated to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Complying with International Pharmacopoeias
5